Skip to main content
Erschienen in: BMC Cancer 1/2023

Open Access 01.12.2023 | Research

Determinants of late-stage cervical cancer presentation in Ethiopia: a systematic review and meta-analysis

verfasst von: Amare Zewdie, Solomon Shitu, Natnael Kebede, Anteneh Gashaw, Habitu Birhan Eshetu, Tenagnework Eseyneh, Abebaw Wasie Kasahun

Erschienen in: BMC Cancer | Ausgabe 1/2023

Abstract

Introduction

Behind breast, colorectal, and lung cancers, cervical cancer is the fourth most common cancer affecting females. Despite, it is a preventable form of cancer both the incidence and mortality figures reflect it as a major reproductive health problem. Late-stage cervical cancer diagnosis is associated with complicated clinical presentation which can result in short survival time and increased mortality. Several factors contribute to the late-stage presentation of cervical cancer patients. In Ethiopia nationally summarized evidence on the level and the factors contributing to late-stage cervical cancer diagnosis is scarce. Therefore, this systematic review and meta-analysis aimed to assess the pooled prevalence of late-stage cervical cancer diagnosis and its determinants in Ethiopia.

Method

A systematic review and meta-analysis were conducted using PRISMA guidelines. Comprehensive literature was searched in PubMed, Embase, Google Scholar, and African Online Journal to retrieve eligible articles. A weighted inverse variance random effect model was used to estimate pooled prevalence. Cochrane Q-test and I2 statistics were computed to assess heterogeneity among studies. Funnel plot and Egger’s regression test were done to assess publication bias.

Result

Overall, 726 articles were retrieved and finally 10 articles were included in this review. The pooled prevalence of late-stage cervical cancer diagnosis in Ethiopia was 60.45% (95%CI; 53.04%-67.85%). Poor awareness about cervical cancer and its treatment (AOR = 1.55, 95% CI: (1.03 – 2.33, longer delay to seek care (AOR = 1.02, 95% CI: (1.01 – 1.03)) and rural residence (AOR = 2.07, 95% CI:( 1.56 – 2.75)) were significantly associated to late-stage diagnosis.

Conclusion

In Ethiopia, six in every ten cervical cancer cases are diagnosed at the late stage of the disease. Poor awareness about cervical cancer and its treatment, long patient delay to seek care, and rural residence were positively associated with late–stage diagnosis. Therefore intervention efforts should be made to improve public awareness about cervical cancer, minimize patient delay to seek care, and expand screening services specifically in the rural residing segment of the population to detect the disease early and improve survival.
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s12885-023-11728-y.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
SRMA
Systematic Reviews and Meta-Analyses

Introduction

Behind breast, colorectal, and lung cancers, cervical cancer is the fourth most common cancer affecting females [1]. Globally, in 2020, there were an estimated 604,127 cases and about 341,831 deaths of cervical cancer [2]. In developing nations, cervical cancer comes in second place behind breast cancer in terms of incidence and death [3]. The highest regional morbidity and mortality of this cancer is in Sub-Saharan Africa in which 70,000 new cases every year are reported [4]. Ethiopia as part of the sub-Saharan region shares the regional high incidence and mortality of cervical cancer which makes it one of the major public health problems in the country. It ranks second in cancer-related mortality next to breast cancer among all women and third cause of cancer deaths among reproductive-age women [5]. Annually, an estimated 6,300 new cervical cancer cases are diagnosed and 4884 deaths occur in Ethiopia [6]. Despite, it is a preventable form of cancer both the incidence and mortality figures in national as well as global contexts reflect it as a major reproductive health problem that affects the quality of life of women [7].
One effective strategy for prevention of maternal death that can be resulted from cervical cancer is early detection of the disease and followed by treatment [8]. Even if cervical cancer screening has been the focus of governmental and non-governmental organizations its implementation on the actual ground is limited in which only 12.87% of eligible women utilized the screening service in sub-Saharan Africa [9]. In Ethiopia, the proportion of eligible women who utilized cervical cancer screening services is not much higher than the regional (sub-Saharan Africa) pooled in which only 14.79% of the eligible women were screened [10]. This very low level of early cervical cancer screening leads to an increment in the number of women that presented with full clinical manifestation and advanced stage of the disease that exposed them to poor prognosis and shortest survival. Thus, the global meta-analysis on the proportion of advanced-stage cervical cancer at diagnosis showed that 60.66% of the cervical cancer cases presented at an advanced or late stage (Stage III and IV) of the disease [11].
A late-stage cervical cancer diagnosis is associated with complicated clinical presentation which can result in short survival time and increased mortality [12]. Several factors contribute to the late-stage presentation of cervical cancer patients. Low level of awareness about the disease and its screening, health system-related delays resulting from lack of screening services and diagnostic facilities, and consideration of traditional healing were the most frequently linked factors to advanced disease presentation of cervical cancer patients [13, 14]. Both the cause and consequences of advanced or end-stage cervical cancer were more aggravated in developing countries specifically in Africa, particularly in the sub-Saharan countries [15]. Thus, the largest proportion of cervical cancer patients present with end-stage of disease with poor prognosis and shortest survival in the continent [16].
So far, in Ethiopia, different studies have been conducted and found a highly variable level of late-stage cervical cancer diagnosis and identified different factors that associate with a late presentation in different parts of the country. Even if there was a global systematic review and meta-analysis on late stage cervical cancer diagnosis [11] it is a global pooled which mixes the developing and developed nation (which have advanced diagnostic and treatment modalities) that has great variation in the prevalence as well as on its predictors. Additionally country (nation) specific evidence on the prevalence and predictors of advanced stage cervical cancer diagnosis is necessary for formulation and implementation of focused policy and programs to alleviate the problem. Up to the level of our knowledge, there is no systematic review and meta-analysis done in Ethiopia which can provide summarized evidence on the level of late-stage cervical cancer diagnosis and its determinants; despite the need to summarize the issue and intervene accordingly. Thus, this systematic review and meta-analysis aimed to assess the pooled prevalence of late-stage breast cancer diagnosis and identify its associated factors in Ethiopia.
The evidence from this systematic review and meta-analysis can be used for planning and implementation of an intervention to reduce late-stage cervical cancer presentation in the country. It identifies the important factors that are associated with late-stage cervical cancer diagnosis, it enables respective stakeholders to target and design evidence-based interventions. This study can also serve as a baseline comparison since there is no systematic review and meta-analysis done on this topic. In addition, it may ignite new insight for further studies that might be conducted on related topics.

Method

Study design and setting

A systematic review and meta-analysis were conducted on determinants of late-stage cervical cancer diagnosis in Ethiopia. Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines were followed (Supplementary Table 1). PRISMA is a protocol consisting of checklists that guide the conduct and reporting of systematic reviews and meta-analyses, which increase the transparency and accuracy of reviews in medicine and other fields [17]. Ethiopia is one of the low-income countries located in the Horn of Africa with a 2022 projected population of 123.4 million, 133.5 million in 2032, and 171.8 million in 2050 [18]. For administrative purposes, Ethiopia is divided into 11 regions and 2 city administrations. Regions are further classified into zones, and zones are divided into districts. Finally, districts are divided into kebele (the smallest administrative division contains 2000 up to 3500 residents).

Search strategies and sources of information

We have checked the PROSPERO database (http://​www.​library.​ucsf.​edu/​) whether published or ongoing projects exist related to the topic to avoid any further duplication. Thus, the findings revealed that there were no ongoing or published articles in the area of this topic. Then this systematic review and meta-analysis were registered in the PROSPERO database with Id no CRD42023441398. Comprehensive literature was searched using international databases PubMed, Embase, Google Scholar, and African Online Journal to retrieve related articles from Jun 1 to 30, 2023. Search terms were formulated using PICO guidelines through online databases. Medical Subject Headings (MeSH) and key terms had been developed using different Boolean operators 'AND' and 'OR'. The following search term was used: "late-stage diagnosis" OR "delayed presentation" OR "delayed diagnosis" OR "advanced stage diagnosis" OR "advanced stage presentation" OR "end-stage diagnosis" OR "end-stage diagnosis" AND “cervical cancer” OR “cervical malignancy” OR “cervical tumor" AND Ethiopia. Grey literature was also searched using Google by exploring the research repository of several universities in the country through their online address using the study topic as a search term.

Eligibility criteria

This systematic review and meta-analysis included all types of studies conducted in Ethiopia which report the prevalence and determinants of late-stage cervical cancer presentation in the English language, without restriction on race or publication date (until the last search date June 30, 2023). Articles without full abstracts or texts and articles reported out of the outcome interest were excluded. Reviews, meta-analyses, editorials, newspaper articles, and other forms of popular media reports were excluded at each respective stage of screening.

Outcome measurements

This study has two main outcomes. The primary outcome was the prevalence of late-stage cervical cancer diagnosis. It is defined as the proportion of participants who have presented or were diagnosed in late or advanced stages (stage III to IV) of cervical cancer at first diagnosis. Therefore, all included studies assessed the study participants' stage of disease and categorized them as diagnosed at the late or early stage of the disease. Then, the response was analyzed and presented as the prevalence of late-stage breast cancer diagnosis. The secondary outcome was determinants of late-stage cervical cancer diagnosis.

Data extraction

All studies obtained from the considered databases were exported to Endnote version X8 software to remove duplicate studies. Then after, all studies were exported to a Microsoft Excel spreadsheet. All authors independently extracted the important data using a standardized data extraction form which was adapted from the Joanna Briggs Institute (JBI) data extraction format. For the first outcome (prevalence) the data extraction format included (primary author, year of publication, regions, study area, sample size, and prevalence with 95% CI) [19]. We extracted data for the second outcome (associated factors to the late-stage cervical cancer diagnosis) using a 2 by 2 table format.

Quality assessment

To assess the quality of each study included in this systematic review and meta-analysis, the modified Newcastle Ottawa Quality Assessment Scale for cross-sectional studies was used [20] (Supplementary Table 2). Two authors (AZ, AWK) assessed the quality of each study (i.e. methodological quality, sample selection, sample size, comparability and the outcome, and statistical analysis of the study). In the case of disagreement between two authors; another two authors (SS, NK) were involved and discussed and resolved the disagreement.

Data processing and analysis

The extracted Microsoft Excel spreadsheet format data was imported to STATA version 17 for analysis. Then weighted inverse variance random effect model was used to estimate the pooled prevalence of late-stage cervical cancer presentation in Ethiopia. A forest plot format was used to present the pooled prevalence of late-stage cervical cancer diagnosis with 95%CI [19]. To identify determinants of late-stage cervical cancer diagnosis, a log odds ratio for each factor was calculated.

Heterogeneity test and publication bias

Cochrane Q-test and I2 statistics were computed to assess heterogeneity among all studies. Accordingly, if the result of I2 is 0% to 40% it is mild heterogeneity, 40 to 70% would be moderate heterogeneity, and 70 to 100% would be considerable heterogeneity [21]. Funnel plot and Eggers test were done to assess publication bias. The p-value > 0.05 indicated that there was no publication bias.

Result

Using our search method, 726 articles were found in the African Journals Online, Embase, Google Scholar, and PubMed databases. 389 duplicate papers were eliminated, 337 items remained. Then, 248 and 56 items were removed after careful examination of their titles and abstracts. Following the evaluation of 33 full-text papers for fulfilment of the inclusion citeria, 23 further articles were excluded for the aforementioned reason. Thus, 10 studies are included in the final systematic review and meta-analysis (Fig. 1).
The included studies in this SRMA comprise 5323 cervical cancer patients. All included studies were cross-sectional. Those studies found a 49.7% to 86.3% prevalence of late-stage cervical cancer diagnosis. Regarding the quality of included studies, the Newcastle Ottawa Quality Assessment scale score of all included studies lies from 7 to 9 which is good (Table 1).
Table 1
Characteristics of included studies in the systematic review and meta-analysis on determinants of late-stage cervical cancer diagnosis in Ethiopia
S.no
Author
Period
Study area
Study design
Sample
Prevalence (%)
Study quality
1
Wassie, et al. [22]
2019
Addis Ababa
Crossect
1057
56.8
Good
2
Dereje, et al. [23]
2017- 2018
Addis Ababa
Crossect
212
60.4
Good
3
Zeleke, et al. [24]
2019
Addis Ababa
Crossect
410
86.3
Good
4
Begoihn, et al. [6]
2008 -2012
Addis Ababa
Crossect
1575
56.3
Good
5
Deressa, et al. [25]
2014
Addis Ababa
Crossect
242
66.1
Good
6
Seifu, et al. [26]
2014 – 2019
Addis Ababa
Crossect
346
49.7
Good
7
Solomon, et al. [27]
2010- 2014
Addis Ababa
Crossect
264
52.7
Good
8
Mebratie, et al. [28]
2017 – 2021
Amhara
Crossect
422
63.5
Good
9
Fitiwe W. [29]
2020
Addis Ababa
Crossect
392
53.8
Good
10
Mose O. [30]
2012 – 2014
Addis Ababa
Crossect
403
58.3
Good

The magnitude of late-stage cervical cancer diagnosis in Ethiopia

The overall late-stage cervical cancer diagnosis in Ethiopia was 60.45% (95%CI; 53.04%-67.85%). The Cochrane heterogeneity index (I2 = 96.8%), P = 0.000, showed significant heterogeneity of several studies (I2 > 70%). A forest plot was used to display the results (Fig. 2).

Publication bias

A funnel plot was used in this systematic review and meta-analysis to test for publication bias at a significance level lower than 0.05. The funnel plot (Fig. 3) and Egger's regression test's P = 0.793 (p > 0.05) (statistically not significance) indicated that there was no evidence of publication bias.

Sensitivity analysis

No single study had affected the overall pooled prevalence of late-stage cervical cancer detection, according to a random-effects model result (Fig. 4).

Determinants of late-stage cervical cancer diagnosis in Ethiopia

The identification of the determinants of late-stage cervical cancer diagnosis in our review includes three variables that are associated to late-stage cervical cancer diagnosis in two or more primary studies. As a result, in Ethiopia, late-stage cervical cancer detection was associated with poor awareness about of cervical cancer and its treatment, patient delay in seeking care, and rural residence. Patients who have poor awareness about cervical cancer and its treatment were 1.55 times more likely to present with late-stage cervical cancer as compared to their counterparts (AOR = 1.55, 95% CI: (1.03 – 2.33)). Similarly, Patients who had a longer delay to seek care were 1.02 times more likely to be diagnosed at an advanced stage as compared to patients who seek care early (AOR = 1.02, 95% CI: (1.01 – 1.03)). Moreover, patients from rural areas were twice more likely to be present at the advanced stage as compared to urban residing patients (AOR = 2.07, 95% CI:( 1.56 – 2.75)) (Table 2).
Table 2
Factors associated with late-stage cervical cancer diagnosis in Ethiopia
Variable
Authors
AOR
95%CI
Pooled AOR
95%CI of pooled AOR
Poor awareness
Zeleke, et al
1.33
1.01–2.71
1.55
1.03 – 2.33
Fitiwe W
2.38
1.03 – 5.11
Longer patient delay to seek care
Dereje, et al
1.31
1.04– 1.71
1.02
1.01 – 1.03
Begoihn, et al
1.004
1.002 – 1.006
Rural residence
Wassie, et al
1.88
1.38 – 2.56
2.07
1.56 – 2.75
Fitiwe W
3.41
1.69 – 6.88

Discussion

Even though cervical cancer is the most preventable form of cancer through human papillomavirus vaccination, effective screening, and treatment of pre-cancerous lesions, it is the most prevalent malignancy among women in developing countries [31]. Due to the poor healthcare setup for early screening and treatment, most patients are diagnosed at an advanced stage and the disease's related mortality is also higher in low and middle-income countries [32]. Globally, also 60.66% of the cervical cancer cases presented at an advanced or late stage (Stage III and IV) of the disease, and the largest share was from Asia (69.3%) and Africa (62.6%) [11]. late-stage diagnosis of cervical cancer resulted in complicated clinical manifestation and poor prognosis which significantly diminish survival [33].
In Ethiopia, several primary studies were conducted and found a variable level of late-stage cervical cancer diagnosis in the country; however, summarized and representative evidence on the level and factors associated with late-stage cervical cancer presentation as a nation was scarce. Thus this SRMA aimed to determine the level and identify contributing factors to late-stage cervical cancer diagnosis in the country. Accordingly, the pooled prevalence of late-stage cervical cancer diagnosis in Ethiopia was 60.45% (95%CI; 53.04%-67.85%). The finding was consistent with study findings from Kenya (53.9%) [34], Uganda (66%) [35], Tanzania (63.9%) [14] Ghana (65.97%) [36], and with the global pooled prevalence of late stage cervical cancer presentation (60.66%) [11]. It was slightly lower than the study finding from Sudan [37] and Nigeria [38]. However, the finding was higher than studies from Morocco (39.9) [39], Mexico (38%) [40], India (39.5%) [41], and England (2.3%) [42]. The possible justification for the existing discrepancy may be the difference in health care setup that the respective country had for early detection of cervical cancer; since the above-listed countries are economically good and have advanced diagnostic facilities that enable them to early detect and treat the disease. Whereas in Ethiopia the infrastructure and the whole health system setup for early detection of cancer are not much pioneering that is why a significant proportion of cervical patients presented with late stage. The finding calls for action to be taken to improve screening of cervical cancer and effort should be made in reducing barriers to early diagnosis of cervical cancer to reduce the proportion of patients that are presented at the end stage of the disease to improve prognosis and survival.
Reducing the proportion of patients presenting with late-stage of cervical cancer requires intervention that targets the contributing factors for late-stage presentation and the barriers to screening. Thus, our review identified poor awareness about cervical cancer and its treatment, patient delays to seek care, and rural residence as contributing factors to late-stage presentation at first diagnosis. Patients who have poor awareness about cervical cancer and its treatment were 55% times more likely to present with late-stage cervical cancer as compared to their counterparts. The finding was in line with study findings in Morocco [39] and Kenya [43] in which patients who have better knowledge about the cause, consequences, and treatment of cervical cancer are less likely to delay for diagnosis and treatment. The finding implies the need to improve public awareness about cervical cancer including its cause, consequence, diagnosis approach, treatment, and prevention methods so as to enable women to be involved in screening and early diagnosis and treatment.
In this review, patients who had a longer delay to seek care were more likely to be diagnosed at an advanced stage as compared to patients who seek care early. The finding was consistent with a study in Nepal in which patients who were late to share their first symptom were prone to advanced-stage diagnosis [44]. This is because patients who visited health institutions early; while they feel the first symptom have a great opportunity to be diagnosed in the early disease phase that can be treated easily and cured. The finding implies the need to expand awareness creation about early symptoms of cervical cancer and improve health-seeking behavior to minimize the delay of patients in seeking cervical cancer diagnosis and treatment care.
Moreover in our review, rural cervical cancer patients were twice more likely to be present at the advanced stage as compared to urban residing patients. This is in line with the global meta-analysis of factors associated with late-stage cervical cancer presentation [11], with studies in Sudan [37] and Morocco [45] in which rurally residing cervical cancer patients are more frequently presented at the late stage of the disease. This might be due to the infrastructure in the rural environment including the health care setup may expose them to both patient and health-system delays which leads them to late-stage presentation. Additionally, patients who live in rural areas cannot also get adequate information about cervical cancer which leads them delayed diagnosis [46]. The finding suggests that cervical cancer screening and awareness creation intervention should target the rurally residing segments of the population to lower the proportion of cervical cancer victims who are presented at the late stage of the disease.
Not standing with its finding, this SRMA has limitation. Our search strategy found primary studies of low methodological quality which are all cross-sectional, especially we have not got high quality randomized control trial studies to increase the validity of the finding.

Conclusion

Six of every ten cervical cancer cases in Ethiopia were diagnosed at an advanced stage, which indicates the health system managers in the country should carefully involve in planning and implementation interventions to lower the proportion of patients diagnosed at the end stage of the disease to enhance prognosis and survival using this current and representative evidence as base line. Poor awareness about cervical cancer and its treatment, long patient delay to seek care, and rural residence were positively associated with late–stage diagnosis. Therefore intervention efforts at all level of the health system setup should be made in improving public awareness about the cause, consequences, diagnosis, and treatment and prevention approach of cervical cancer. Minimizing patient delay to seek care and expansion of screening services specifically in the rural residing segment of the population should be the focus of intervention so as to detect the disease early and improve survival. Future researches should focus in exploring the determinants of late stage cervical cancer diagnosis using high quality study methods.

Acknowledgements

We would like to thank all authors of the primary studies which are included in this systematic review and meta-analysis.

Institutional review board statement

Not applicable. This systematic review and meta-analysis used and analyzed information obtained from pre-existing studies.

Declarations

Not applicable.
Not applicable.

Competing interests

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Zurück zum Zitat Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, Arbyn M, Basu P, Bray F, Vaccarella S. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11(2):e197-206.CrossRefPubMed Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, Arbyn M, Basu P, Bray F, Vaccarella S. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11(2):e197-206.CrossRefPubMed
3.
Zurück zum Zitat Wilailak S, Kengsakul M, Kehoe S. Worldwide initiatives to eliminate cervical cancer. Int J Gynecol Obstet. 2021;155:102–6.CrossRef Wilailak S, Kengsakul M, Kehoe S. Worldwide initiatives to eliminate cervical cancer. Int J Gynecol Obstet. 2021;155:102–6.CrossRef
4.
Zurück zum Zitat Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86.CrossRefPubMed Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86.CrossRefPubMed
5.
Zurück zum Zitat HPV IICo, Cancer. Human Papillomavirus and Related Diseases Report. Worldwide; 2016. HPV IICo, Cancer. Human Papillomavirus and Related Diseases Report. Worldwide; 2016.
6.
Zurück zum Zitat Begoihn M, Mathewos A, Aynalem A, Wondemagegnehu T, Moelle U, Gizaw M, et al. Cervical cancer in Ethiopia–predictors of advanced stage and prolonged time to diagnosis. Infect Agents Cancer. 2019;14(1):1–7.CrossRef Begoihn M, Mathewos A, Aynalem A, Wondemagegnehu T, Moelle U, Gizaw M, et al. Cervical cancer in Ethiopia–predictors of advanced stage and prolonged time to diagnosis. Infect Agents Cancer. 2019;14(1):1–7.CrossRef
7.
Zurück zum Zitat Lopes VAS, Ribeiro JM. Cervical cancer control limiting factors and facilitators: a literature review. Cien Saude Colet. 2019;24:3431–42.CrossRefPubMed Lopes VAS, Ribeiro JM. Cervical cancer control limiting factors and facilitators: a literature review. Cien Saude Colet. 2019;24:3431–42.CrossRefPubMed
8.
Zurück zum Zitat Kessler TA, editor Cervical cancer: prevention and early detection. Seminars in oncology nursing; 2017: Elsevier. Kessler TA, editor Cervical cancer: prevention and early detection. Seminars in oncology nursing; 2017: Elsevier.
9.
Zurück zum Zitat Yimer NB, Mohammed MA, Solomon K, Tadese M, Grutzmacher S, Meikena HK, et al. Cervical cancer screening uptake in Sub-Saharan Africa: a systematic review and meta-analysis. Public Health. 2021;195:105–11.CrossRefPubMed Yimer NB, Mohammed MA, Solomon K, Tadese M, Grutzmacher S, Meikena HK, et al. Cervical cancer screening uptake in Sub-Saharan Africa: a systematic review and meta-analysis. Public Health. 2021;195:105–11.CrossRefPubMed
10.
Zurück zum Zitat Desta M, Getaneh T, Yeserah B, Worku Y, Eshete T, Birhanu MY, et al. Cervical cancer screening utilization and predictors among eligible women in Ethiopia: A systematic review and meta-analysis. PLoS One. 2021;16(11):e0259339.CrossRefPubMedPubMedCentral Desta M, Getaneh T, Yeserah B, Worku Y, Eshete T, Birhanu MY, et al. Cervical cancer screening utilization and predictors among eligible women in Ethiopia: A systematic review and meta-analysis. PLoS One. 2021;16(11):e0259339.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Tekalign T, Teshome M. Prevalence and determinants of late-stage presentation among cervical cancer patients, a systematic review and meta-analysis. PLoS One. 2022;17(4):e0267571 PubMed PMID: 35476851. Pubmed Central PMCID: PMC9045598. Epub 2022/04/28. eng.CrossRefPubMedPubMedCentral Tekalign T, Teshome M. Prevalence and determinants of late-stage presentation among cervical cancer patients, a systematic review and meta-analysis. PLoS One. 2022;17(4):e0267571 PubMed PMID: 35476851. Pubmed Central PMCID: PMC9045598. Epub 2022/04/28. eng.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Landy R, Pesola F, Castañón A, Sasieni P. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case–control study. Br J Cancer. 2016;115(9):1140–6.CrossRefPubMedPubMedCentral Landy R, Pesola F, Castañón A, Sasieni P. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case–control study. Br J Cancer. 2016;115(9):1140–6.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Birhanu Z, Abdissa A, Belachew T, Deribew A, Segni H, Tsu V, et al. Health seeking behavior for cervical cancer in Ethiopia: a qualitative study. Int J Equity Health. 2012;11(1):1–8.CrossRef Birhanu Z, Abdissa A, Belachew T, Deribew A, Segni H, Tsu V, et al. Health seeking behavior for cervical cancer in Ethiopia: a qualitative study. Int J Equity Health. 2012;11(1):1–8.CrossRef
14.
Zurück zum Zitat Mlange R, Matovelo D, Rambau P, Kidenya B. Patient and disease characteristics associated with late tumour stage at presentation of cervical cancer in northwestern Tanzania. BMC Womens Health. 2015;16(1):1–6. Mlange R, Matovelo D, Rambau P, Kidenya B. Patient and disease characteristics associated with late tumour stage at presentation of cervical cancer in northwestern Tanzania. BMC Womens Health. 2015;16(1):1–6.
15.
Zurück zum Zitat Stewart TS, Moodley J, Walter FM. Population risk factors for late-stage presentation of cervical cancer in sub-Saharan Africa. Cancer Epidemiol. 2018;53:81–92.CrossRefPubMed Stewart TS, Moodley J, Walter FM. Population risk factors for late-stage presentation of cervical cancer in sub-Saharan Africa. Cancer Epidemiol. 2018;53:81–92.CrossRefPubMed
16.
Zurück zum Zitat Sengayi-Muchengeti M, Joko-Fru WY, Miranda-Filho A, Egue M, Akele-Akpo MT, N’da G, et al. Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index: A population-based registry study. Int J Cancer. 2020;147(11):3037–48.CrossRefPubMed Sengayi-Muchengeti M, Joko-Fru WY, Miranda-Filho A, Egue M, Akele-Akpo MT, N’da G, et al. Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index: A population-based registry study. Int J Cancer. 2020;147(11):3037–48.CrossRefPubMed
17.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, Group* P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med. 2009;151(4):264–9.CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, Group* P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med. 2009;151(4):264–9.CrossRef
18.
Zurück zum Zitat Bekele A, Lakew Y. Projecting Ethiopian demographics from 2012–2050 using the spectrum suite of models. Ethiop Public Health Assoc. 2014;4. Bekele A, Lakew Y. Projecting Ethiopian demographics from 2012–2050 using the spectrum suite of models. Ethiop Public Health Assoc. 2014;4.
19.
Zurück zum Zitat Zewdie A, Kasahun AW, Habtie A, Gashaw A, Ayele M. Human papillomavirus vaccine acceptance among adolescent girls in Ethiopia: a systematic review and meta-analysis. BMC Public Health. 2023;23(1):1369 (PubMed PMID: 37461006. Pubmed Central PMCID: PMC10353090. Epub 2023/07/18. eng).CrossRefPubMedPubMedCentral Zewdie A, Kasahun AW, Habtie A, Gashaw A, Ayele M. Human papillomavirus vaccine acceptance among adolescent girls in Ethiopia: a systematic review and meta-analysis. BMC Public Health. 2023;23(1):1369 (PubMed PMID: 37461006. Pubmed Central PMCID: PMC10353090. Epub 2023/07/18. eng).CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat McPheeters ML, Kripalani S, Peterson NB, Idowu RT, Jerome RN, Potter SA, et al. Closing the quality gap: revisiting the state of the science (vol. 3: quality improvement interventions to address health disparities). Evidence report/technology assessment. 2012 (208.3):1–475. McPheeters ML, Kripalani S, Peterson NB, Idowu RT, Jerome RN, Potter SA, et al. Closing the quality gap: revisiting the state of the science (vol. 3: quality improvement interventions to address health disparities). Evidence report/technology assessment. 2012 (208.3):1–475.
21.
Zurück zum Zitat Thorlund K, Imberger G, Johnston BC, Walsh M, Awad T, Thabane L, et al. Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS One. 2012;7(7):e39471.CrossRefPubMedPubMedCentral Thorlund K, Imberger G, Johnston BC, Walsh M, Awad T, Thabane L, et al. Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS One. 2012;7(7):e39471.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Wassie M, Fentie B. Prevalence of late-stage presentation and associated factors of cervical cancer patients in Tikur Anbesa Specialized Hospital, Ethiopia: institutional based cross-sectional study. Infect Agents Cancer. 2021;16(1):30.CrossRef Wassie M, Fentie B. Prevalence of late-stage presentation and associated factors of cervical cancer patients in Tikur Anbesa Specialized Hospital, Ethiopia: institutional based cross-sectional study. Infect Agents Cancer. 2021;16(1):30.CrossRef
23.
Zurück zum Zitat Dereje N, Gebremariam A, Addissie A, Worku A, Assefa M, Abraha A, et al. Factors associated with advanced stage at diagnosis of cervical cancer in Addis Ababa, Ethiopia: a population-based study. BMJ Open. 2020;10(10):e040645.CrossRefPubMedPubMedCentral Dereje N, Gebremariam A, Addissie A, Worku A, Assefa M, Abraha A, et al. Factors associated with advanced stage at diagnosis of cervical cancer in Addis Ababa, Ethiopia: a population-based study. BMJ Open. 2020;10(10):e040645.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Zeleke S, Anley M, Kefale D, Wassihun B. Factors associated with delayed diagnosis of cervical cancer in tikur anbesa specialized hospital, Ethiopia, 2019: cross-sectional study. Cancer Manag Res. 2021:579-85. Zeleke S, Anley M, Kefale D, Wassihun B. Factors associated with delayed diagnosis of cervical cancer in tikur anbesa specialized hospital, Ethiopia, 2019: cross-sectional study. Cancer Manag Res. 2021:579-85.
25.
Zurück zum Zitat Deressa BT, Assefa M, Tafesse E, Kantelhardt EJ, Soldatovic I, Cihoric N, et al. Contemporary treatment patterns and survival of cervical cancer patients in Ethiopia. BMC Cancer. 2021;21(1):1–7.CrossRef Deressa BT, Assefa M, Tafesse E, Kantelhardt EJ, Soldatovic I, Cihoric N, et al. Contemporary treatment patterns and survival of cervical cancer patients in Ethiopia. BMC Cancer. 2021;21(1):1–7.CrossRef
26.
Zurück zum Zitat Seifu B, Fikru C, Yilma D, Tessema F. Predictors of time to death among cervical cancer patients at Tikur Anbesa specialized hospital from 2014 to 2019: A survival analysis. PLoS One. 2022;17(2):e0264369.CrossRefPubMedPubMedCentral Seifu B, Fikru C, Yilma D, Tessema F. Predictors of time to death among cervical cancer patients at Tikur Anbesa specialized hospital from 2014 to 2019: A survival analysis. PLoS One. 2022;17(2):e0264369.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Mebratie AE, Moges NA, Meselu BT, Melesse MF. Time to death from cervical cancer and predictors among cervical cancer patients in Felege Hiwot Comprehensive Specialized Hospital, North West Ethiopia: facility-based retrospective follow-up study. PLoS One. 2022;17(6):e0269576.CrossRefPubMedPubMedCentral Mebratie AE, Moges NA, Meselu BT, Melesse MF. Time to death from cervical cancer and predictors among cervical cancer patients in Felege Hiwot Comprehensive Specialized Hospital, North West Ethiopia: facility-based retrospective follow-up study. PLoS One. 2022;17(6):e0269576.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Fitiwe W. Magnitude and Factors Associated with Late Stage at Diagnosis of Cervical Cancer Patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia 2020. Fitiwe W. Magnitude and Factors Associated with Late Stage at Diagnosis of Cervical Cancer Patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia 2020.
30.
Zurück zum Zitat Mose O. Five-year survival status of women diagnosed with cervical cancer and treatment impact at Tikur Anbessa hospital, Addis Ababa, Ethiopia; a retrospective cohort study 2021. Mose O. Five-year survival status of women diagnosed with cervical cancer and treatment impact at Tikur Anbessa hospital, Addis Ababa, Ethiopia; a retrospective cohort study 2021.
31.
Zurück zum Zitat Beddoe AM. Elimination of cervical cancer: challenges for developing countries. ecancermedicalscience. 2019;13. Beddoe AM. Elimination of cervical cancer: challenges for developing countries. ecancermedicalscience. 2019;13.
32.
Zurück zum Zitat Hull R, Mbele M, Makhafola T, Hicks C, Wang SM, Reis RM, et al. Cervical cancer in low and middle-income countries. Oncol Lett. 2020;20(3):2058–74.CrossRefPubMedPubMedCentral Hull R, Mbele M, Makhafola T, Hicks C, Wang SM, Reis RM, et al. Cervical cancer in low and middle-income countries. Oncol Lett. 2020;20(3):2058–74.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Perri T, Issakov G, Ben-Baruch G, Felder S, Beiner ME, Helpman L, et al. Effect of treatment delay on survival in patients with cervical cancer: a historical cohort study. Int J Gynecol Cancer. 2014;24(7):1326–32.CrossRefPubMed Perri T, Issakov G, Ben-Baruch G, Felder S, Beiner ME, Helpman L, et al. Effect of treatment delay on survival in patients with cervical cancer: a historical cohort study. Int J Gynecol Cancer. 2014;24(7):1326–32.CrossRefPubMed
34.
Zurück zum Zitat Frida KM, Atieno WMC, Habtu M. Socio-demographic factors associated with advanced stage of cervical cancer at diagnosis in kenyatta national hospital. A cross sectional study: Kenya; 2017. Frida KM, Atieno WMC, Habtu M. Socio-demographic factors associated with advanced stage of cervical cancer at diagnosis in kenyatta national hospital. A cross sectional study: Kenya; 2017.
35.
Zurück zum Zitat Mwaka AD, Garimoi CO, Were EM, Roland M, Wabinga H, Lyratzopoulos G. Social, demographic and healthcare factors associated with stage at diagnosis of cervical cancer: cross-sectional study in a tertiary hospital in Northern Uganda. BMJ Open. 2016;6(1):e007690.CrossRefPubMedPubMedCentral Mwaka AD, Garimoi CO, Were EM, Roland M, Wabinga H, Lyratzopoulos G. Social, demographic and healthcare factors associated with stage at diagnosis of cervical cancer: cross-sectional study in a tertiary hospital in Northern Uganda. BMJ Open. 2016;6(1):e007690.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Dunyo P, Effah K, Udofia EA. Factors associated with late presentation of cervical cancer cases at a district hospital: a retrospective study. BMC Public Health. 2018;18:1–10. Dunyo P, Effah K, Udofia EA. Factors associated with late presentation of cervical cancer cases at a district hospital: a retrospective study. BMC Public Health. 2018;18:1–10.
37.
Zurück zum Zitat Ibrahim A, Rasch V, Pukkala E, Aro AR. Predictors of cervical cancer being at an advanced stage at diagnosis in Sudan. Int J Women’s Health. 2011;3:385–9.CrossRef Ibrahim A, Rasch V, Pukkala E, Aro AR. Predictors of cervical cancer being at an advanced stage at diagnosis in Sudan. Int J Women’s Health. 2011;3:385–9.CrossRef
38.
Zurück zum Zitat Anorlu R, Orakwue C, Oyeneyin L, Abudu O. Late presentation of patients with cervical cancer to a tertiary hospital in Lagos: what is responsible? Eur J Gynaecol Oncol. 2004;25(6):729–32.PubMed Anorlu R, Orakwue C, Oyeneyin L, Abudu O. Late presentation of patients with cervical cancer to a tertiary hospital in Lagos: what is responsible? Eur J Gynaecol Oncol. 2004;25(6):729–32.PubMed
39.
Zurück zum Zitat Ouasmani F, Hanchi Z, Haddou Rahou B, Bekkali R, Ahid S, Mesfioui A. Determinants of patient delay in seeking diagnosis and treatment among Moroccan women with cervical cancer. Obstet Gynecol Int. 2016;2016:4840762.CrossRefPubMedPubMedCentral Ouasmani F, Hanchi Z, Haddou Rahou B, Bekkali R, Ahid S, Mesfioui A. Determinants of patient delay in seeking diagnosis and treatment among Moroccan women with cervical cancer. Obstet Gynecol Int. 2016;2016:4840762.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Unger-Saldaña K, Alvarez-Meneses A, Isla-Ortiz D. Symptomatic presentation, diagnostic delays and advanced stage among cervical cancer patients in Mexico; 2018. Unger-Saldaña K, Alvarez-Meneses A, Isla-Ortiz D. Symptomatic presentation, diagnostic delays and advanced stage among cervical cancer patients in Mexico; 2018.
41.
Zurück zum Zitat Chopra S, Gupta M, Mathew A, Mahantshetty U, Engineer R, Lavanya G, et al. Locally advanced cervical cancer: a study of 5-year outcomes. Indian J Cancer. 2018;55(1):45–9.CrossRefPubMed Chopra S, Gupta M, Mathew A, Mahantshetty U, Engineer R, Lavanya G, et al. Locally advanced cervical cancer: a study of 5-year outcomes. Indian J Cancer. 2018;55(1):45–9.CrossRefPubMed
42.
Zurück zum Zitat Lim AW, Ramirez AJ, Hamilton W, Sasieni P, Patnick J, Forbes LJ. Delays in diagnosis of young females with symptomatic cervical cancer in England: an interview-based study. Br J Gen Pract. 2014;64(627):e602–10.CrossRefPubMedPubMedCentral Lim AW, Ramirez AJ, Hamilton W, Sasieni P, Patnick J, Forbes LJ. Delays in diagnosis of young females with symptomatic cervical cancer in England: an interview-based study. Br J Gen Pract. 2014;64(627):e602–10.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Wamburu K, Busakhala N, Owuor K, Nyagero J. Association between stage at diagnosis and knowledge on cervical cancer among patients in a Kenyan tertiary hospital: a cross-sectional study. Pan Afr Med J. 2016;25(Suppl 2):15.PubMedPubMedCentral Wamburu K, Busakhala N, Owuor K, Nyagero J. Association between stage at diagnosis and knowledge on cervical cancer among patients in a Kenyan tertiary hospital: a cross-sectional study. Pan Afr Med J. 2016;25(Suppl 2):15.PubMedPubMedCentral
44.
Zurück zum Zitat Gyenwali D, Pariyar J, Onta SR. Factors associated with late diagnosis of cervical cancer in Nepal. Asian Pac J Cancer Prev. 2013;14(7):4373–7.CrossRefPubMed Gyenwali D, Pariyar J, Onta SR. Factors associated with late diagnosis of cervical cancer in Nepal. Asian Pac J Cancer Prev. 2013;14(7):4373–7.CrossRefPubMed
45.
Zurück zum Zitat Berraho M, Obtel M, Bendahhou K, Zidouh A, Errihani H, Benider A, et al. Sociodemographic factors and delay in the diagnosis of cervical cancer in Morocco. Pan Afr Med J. 2012;12(1):14.PubMedPubMedCentral Berraho M, Obtel M, Bendahhou K, Zidouh A, Errihani H, Benider A, et al. Sociodemographic factors and delay in the diagnosis of cervical cancer in Morocco. Pan Afr Med J. 2012;12(1):14.PubMedPubMedCentral
46.
Zurück zum Zitat Buchanan Lunsford N, Ragan K, Lee Smith J, Saraiya M, Aketch M. Environmental and psychosocial barriers to and benefits of cervical cancer screening in Kenya. Oncologist. 2017;22(2):173–81.CrossRefPubMedPubMedCentral Buchanan Lunsford N, Ragan K, Lee Smith J, Saraiya M, Aketch M. Environmental and psychosocial barriers to and benefits of cervical cancer screening in Kenya. Oncologist. 2017;22(2):173–81.CrossRefPubMedPubMedCentral
Metadaten
Titel
Determinants of late-stage cervical cancer presentation in Ethiopia: a systematic review and meta-analysis
verfasst von
Amare Zewdie
Solomon Shitu
Natnael Kebede
Anteneh Gashaw
Habitu Birhan Eshetu
Tenagnework Eseyneh
Abebaw Wasie Kasahun
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2023
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11728-y

Weitere Artikel der Ausgabe 1/2023

BMC Cancer 1/2023 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.